Literature DB >> 18234800

Efficient in vitro expansion of human immunodeficiency virus (HIV)-specific T-cell responses by gag mRNA-electroporated dendritic cells from treated and untreated HIV type 1-infected individuals.

Ellen R Van Gulck1, Guido Vanham, Leo Heyndrickx, Sandra Coppens, Katleen Vereecken, Derek Atkinson, Eric Florence, Ilse Kint, Zwi Nisan Berneman, Viggo Van Tendeloo.   

Abstract

Developing an immunotherapy to keep human immunodeficiency virus type 1 (HIV-1) replication suppressed while discontinuing highly active antiretroviral therapy (HAART) is an important challenge. In the present work, we evaluated in vitro whether dendritic cells (DC) electroporated with gag mRNA can induce HIV-specific responses in T cells from chronically infected subjects. Monocyte-derived DC, from therapy-naïve and HAART-treated HIV-1-seropositive subjects, that were electroporated with consensus codon-optimized HxB2 gag mRNA efficiently expanded T cells, secreting gamma interferon (IFN-gamma) and interleukin 2 (IL-2), as well as other cytokines and perforin, upon restimulation with a pool of overlapping Gag peptides. The functional expansion levels after 1 week of stimulation were comparable in T cells from HAART-treated and treatment-naïve patients and involved both CD4(+) and CD8(+) T cells, with evidence of bifunctionality in T cells. Epitope mapping of p24 showed that stimulated T cells had a broadened response toward previously nondescribed epitopes. DC, from HAART-treated subjects, that were electroporated with autologous proviral gag mRNA equally efficiently expanded HIV-specific T cells. Regulatory T cells did not prevent the induction of effector T cells in this system, whereas the blocking of PD-L1 slightly increased the induction of T-cell responses. This paper shows that DC, loaded with consensus or autologous gag mRNA, expand HIV-specific T-cell responses in vitro.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18234800      PMCID: PMC2268461          DOI: 10.1128/JVI.02080-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  70 in total

1.  Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells.

Authors:  V F Van Tendeloo; P Ponsaerts; F Lardon; G Nijs; M Lenjou; C Van Broeckhoven; D R Van Bockstaele; Z N Berneman
Journal:  Blood       Date:  2001-07-01       Impact factor: 22.113

2.  PD-1 up-regulation is correlated with HIV-specific memory CD8+ T-cell exhaustion in typical progressors but not in long-term nonprogressors.

Authors:  Ji-Yuan Zhang; Zheng Zhang; Xicheng Wang; Jun-Liang Fu; Jinxia Yao; Yanmei Jiao; Liangen Chen; Hui Zhang; Jianan Wei; Lei Jin; Ming Shi; George Fu Gao; Hao Wu; Fu-Sheng Wang
Journal:  Blood       Date:  2007-02-01       Impact factor: 22.113

Review 3.  PD-1 and its ligands in T-cell immunity.

Authors:  Mary E Keir; Loise M Francisco; Arlene H Sharpe
Journal:  Curr Opin Immunol       Date:  2007-04-12       Impact factor: 7.486

Review 4.  Role of cellular immunity in protection against HIV infection.

Authors:  S Rowland-Jones; R Tan; A McMichael
Journal:  Adv Immunol       Date:  1997       Impact factor: 3.543

Review 5.  Escape of human immunodeficiency virus from immune control.

Authors:  A J McMichael; R E Phillips
Journal:  Annu Rev Immunol       Date:  1997       Impact factor: 28.527

Review 6.  Gene-based cancer vaccines: an ex vivo approach.

Authors:  V F Van Tendeloo; C Van Broeckhoven; Z N Berneman
Journal:  Leukemia       Date:  2001-04       Impact factor: 11.528

7.  In vitro human immunodeficiency virus eradication by autologous CD8(+) T cells expanded with inactivated-virus-pulsed dendritic cells.

Authors:  W Lu; J M Andrieu
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

8.  Human dendritic cells transfected with either RNA or DNA encoding influenza matrix protein M1 differ in their ability to stimulate cytotoxic T lymphocytes.

Authors:  I Strobel; S Berchtold; A Götze; U Schulze; G Schuler; A Steinkasserer
Journal:  Gene Ther       Date:  2000-12       Impact factor: 5.250

9.  Effects of structured treatment interruptions on metabolic, anthropometric, immunologic, and quality of life outcomes in HIV-positive adults on HAART.

Authors:  Renato Maserati; Andrea Foli; Lina Tomasoni; Laura Sighinolfi; Franco Maggiolo; Daria Sacchini; Massimo Di Pietro; Davide Bertelli; Carmine Tinelli; Franco Lori
Journal:  Curr HIV Res       Date:  2007-05       Impact factor: 1.581

10.  Expression of PD-L1, a marker of disease status, is not reduced by HAART in aviraemic patients.

Authors:  Guglielmo Rosignoli; Alison Cranage; Catherine Burton; Mark Nelson; Alan Steel; Brian Gazzard; Frances Gotch; Nesrina Imami
Journal:  AIDS       Date:  2007-06-19       Impact factor: 4.177

View more
  11 in total

1.  Mobilizing monocytes to cross-present circulating viral antigen in chronic infection.

Authors:  Adam J Gehring; Muzlifah Haniffa; Patrick T Kennedy; Zi Zong Ho; Carolina Boni; Amanda Shin; Nasirah Banu; Adeline Chia; Seng Gee Lim; Carlo Ferrari; Florent Ginhoux; Antonio Bertoletti
Journal:  J Clin Invest       Date:  2013-08-01       Impact factor: 14.808

2.  Monocyte-derived dendritic cells from cirrhotic patients retain similar capacity for maturation/activation and antigen presentation as those from healthy subjects.

Authors:  Shiroh Tanoue; Li-Yuan Chang; Yonghai Li; David E Kaplan
Journal:  Cell Immunol       Date:  2015-02-25       Impact factor: 4.868

3.  Polyelectrolyte capsules-containing HIV-1 p24 and poly I:C modulate dendritic cells to stimulate HIV-1-specific immune responses.

Authors:  Winni De Haes; Stefaan De Koker; Charlotte Pollard; Derek Atkinson; Erika Vlieghe; Jessy Hoste; Joanna Rejman; Stefaan De Smedt; Johan Grooten; Guido Vanham; Ellen Van Gulck
Journal:  Mol Ther       Date:  2010-05-11       Impact factor: 11.454

4.  Preclinical evaluation of HIV-1 therapeutic ex vivo dendritic cell vaccines expressing consensus Gag antigens and conserved Gag epitopes.

Authors:  Liguo Niu; James M Termini; Saravana K Kanagavelu; Sachin Gupta; Morgane M Rolland; Viraj Kulkarni; George N Pavlakis; Barbara K Felber; James I Mullins; Margaret A Fischl; Geoffrey W Stone
Journal:  Vaccine       Date:  2011-01-15       Impact factor: 3.641

Review 5.  Dendritic cell-based human immunodeficiency virus vaccine.

Authors:  C R Rinaldo
Journal:  J Intern Med       Date:  2009-01       Impact factor: 8.989

Review 6.  T-cell therapies for HIV.

Authors:  Sharon Lam; Catherine Bollard
Journal:  Immunotherapy       Date:  2013-04       Impact factor: 4.196

7.  CD34-derived dendritic cells transfected ex vivo with HIV-Gag mRNA induce polyfunctional T-cell responses in nonhuman primates.

Authors:  Gabrielle Romain; Ellen van Gulck; Olivier Epaulard; Sangkon Oh; Dapeng Li; Gerard Zurawski; Sandra Zurawski; Antonio Cosma; Lucille Adam; Catherine Chapon; Biliana Todorova; Jacques Banchereau; Nathalie Dereuddre-Bosquet; Guido Vanham; Roger Le Grand; Frédéric Martinon
Journal:  Eur J Immunol       Date:  2012-07-04       Impact factor: 5.532

8.  Fusion of ubiquitin to HIV gag impairs human monocyte-derived dendritic cell maturation and reduces ability to induce gag T cell responses.

Authors:  Shanthi Herath; Adel Benlahrech; Timos Papagatsias; Takis Athanasopoulos; Zineb Bouzeboudjen; Catherine Hervouet; Linda Klavinskis; Andrea Meiser; Peter Kelleher; George Dickson; Steven Patterson
Journal:  PLoS One       Date:  2014-02-05       Impact factor: 3.240

9.  Interleukin-12p70 expression by dendritic cells of HIV-1-infected patients fails to stimulate gag-specific immune responses.

Authors:  Ellen Van Gulck; Nathalie Cools; Derek Atkinson; Lotte Bracke; Katleen Vereecken; Marc Vekemans; Viggo F I Van Tendeloo; Zwi N Berneman; Guido Vanham
Journal:  Clin Dev Immunol       Date:  2012-07-12

Review 10.  Optimizing dendritic cell-based immunotherapy: tackling the complexity of different arms of the immune system.

Authors:  Ilse Van Brussel; Zwi N Berneman; Nathalie Cools
Journal:  Mediators Inflamm       Date:  2012-07-18       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.